**Additional File 2. GITR expression by CD4+, CD8+, and FoxP3+ cells**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **Diagnosis** | **Cohort** | **Visit** | **CD4, % Positive\*** | **CD8, % Positive\*** | **FoxP3, % Positive\*** | **GITR, % Positive\*** |
| 1 | CRC | 180 mg | Screening C3, D43 | <1 1 | <1 <1 | 3 1 | 0 0 |
| 2 | SCCHN | 180 mg | Screening C3, D43 | Missing <1 | Missing 1 | 1 1 | 1 0 |
| 3 | TCC | 180 mg | Screening C3, D43 | 5 5 | 1 1 | 1 2 | 3 0 |
| 4 | CRC | 360 mg | Screening C3, D43 | 1 1 | 1 1 | 1 2 | 2 0 |
| 5 | SCCHN | 360 mg | Screening C3, D43 | 5 1 | 1 1 | 5 1 | 10 0 |
| 6 | NSCLC | 360 mg | Screening C3, D43 | Missing Missing | 15 10 | 3 3 | 0 0 |
| 7 | SCCHN | 600 mg | Screening C3, D43 | 40  25 | 30 15 | 5 5 | 10 0 |
| 8 | SCCHN | 600 mg | Screening C3, D43 | 3 5 | 5 1 | 5 5 | 3 0 |
| 9 | TCC | 600 mg | Screening C3, D43 | 1 0 | 1 0 | <1 1 | 0 0 |
| 10 | CRC | 1200 mg | Screening C3, D43 | 30 60 | 50  40 | 5 8 | 1 0 |
| 11 | SCCHN | 1200 mg | Screening C3, D43 | 40 60 | 50 40 | 5 15 | 0 0 |
| 12 | CRC | 1200 mg | Screening C3, D43 | 40 30 | 20 50 | 20 0 | 10 1 |

CRC, colorectal cancer; NSCLC, non–small-cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; TCC, transitional carcinoma of the bladder.

aResult of 5% or greater is positive.